Objectives. The development of RA includes a phase of arthralgia preceding clinical arthritis. The aetiology of symptoms of arthralgia is unclear. Since subclinical joint inflammation is expected to be causally related to pain, we aimed to study associations between subclinical MRI-detected inflammation and pain in patients with arthralgia suspicious for progression to RA.
Introduction
The development of RA can be preceded by several preclinical phases, including a phase of symptoms without clinical synovitis [1] . Identification of patients in this early phase is challenging, but presumably important, as very early recognition and treatment of RA might result in better disease outcomes [26] . A EULAR taskforce recently developed a clinical definition of arthralgia suspicious for progression to RA [7] . This serves to homogenize the group of arthralgia patients considered at risk for RA. To achieve optimal prediction of RA development, information on biomarkers needs to be added to this clinical definition of arthralgia.
Although it is known that symptoms in the pre-arthritis phase of arthralgia can be considerable and can lead to functional limitations that are as restrictive as in the arthritis phase [8] , the origin of the symptoms in this phase is insufficiently known [9] . Previous MRI and ultrasound studies have suggested an association between subclinical MRI-detected inflammation and pain [1012] . However, these studies were small, did not compare ACPA-positive and ACPA-negative arthralgia patients and/or these studies did not evaluate bone marrow oedema (BME) and tenosynovitis as features of subclinical inflammation. Consequently, the association between subclinical inflammation and arthralgia remains largely unstudied.
With the ultimate aim to improve the understanding of the aetiology of symptoms in patients with arthralgia suspicious for progression to RA, this large, cross-sectional MRI study determined whether pain, both at patient and at joint level, can be explained by the presence of subclinical inflammation, evaluating synovitis, BME and tenosynovitis by MRI. Since ACPA-positive and ACPA-negative RA are sub-entities of RA with differences in aetiopathology, it was also studied whether these associations were different in ACPA-positive and ACPA-negative patients [1315] . Finally, the patients with arthralgia suspicious for progression to RA that indeed developed inflammatory arthritis over time were studied separately in a sub-analysis, as in these patients the arthralgia was definitely a preceding phase of inflammatory arthritis.
Methods

Patients
All studied patients were included in the Leiden clinically suspect arthralgia cohort that started in April 2012 [16] . Patients with clinically suspect arthralgia have recentonset (<1 year) arthralgia of the small joints of the hand or feet joints, and imminent RA was considered the most likely cause of symptoms based on the clinical expertise of the rheumatologist. Per definition, clinically suspect arthralgia was not present in case of clinical synovitis or when another more likely explanation for the symptoms (e.g. fibromyalgia or osteoarthritis) was present. Previous use of DMARDs was an exclusion criterion. Patients were followed for 2 years or until development of clinical synovitis. No DMARDs were given while patients were in the clinically suspect arthralgia cohort. At inclusion, a medical history was taken, a physical examination including a 68 tender joint count (68-TJC) was performed, lab samples including determination of ACPA (EliA CCP2, Phadia, Nieuwegein, The Netherlands; positive if 57 U/mL) were taken, and questionnaires on initial and current symptoms were completed by both the patient and the rheumatologist. In October 2017, MRI and clinical data were available for 505 patients. Next, the EULAR definition for arthralgia suspicious for progression to RA was applied on all patients. This definition is intended to be used on top of the clinical identification of clinically suspect arthralgia and serves to create a more homogeneous group of patients with an increased risk on RA [7] . In line with the definition, the EULAR definition was applied to all 505 patients with a clinical suspicion of imminent RA. A total of 325 clinically suspect arthralgia patients fulfilled the definition (presence of three or more parameters) and these patients were studied here [7, 17] . The clinically suspect arthralgia cohort has been approved by the local medical ethical committee of the Leiden University Medical Centre and all patients provided written informed consent.
MRI
A unilateral MRI of the wrist, MCP (25) joints and MTP (15) joints was performed within 2 weeks after inclusion in the clinically suspect arthralgia cohort, using an ONI-MSK-extreme 1.5 T extremity MR scanner (GE, Wisconsin, USA). The MRI was made of the most painful side, or in case of equal symptoms, of the dominant side. Detailed information about the scanning protocol has been described previously [16, 18] and can be found in the supplementary data, section Methods, available at Rheumatology online. MRIs were scored on the presence of BME and synovitis in line with the RA MRI scoring method [1921] . Tenosynovitis was scored according to the method described by Haavardsholm et al. [22] . Tenosynovitis was not assessed in the MTP joints as no validated scoring system for tenosynovitis exists for these joints. Furthermore, for the first 52 patients imaging of MTP joints was limited to pre-contrast sequences in the axial direction (for more details see supplementary data, section Methods, available at Rheumatology online). All MRIs were scored by two trained readers (all intraand interreader correlation coefficients were >0.9, supplementary Table S1, available at Rheumatology online). The mean scores of two readers were studied. At patient level the total inflammation score was defined as the sum of the synovitis, tenosynovitis and BME scores. At joint level the total inflammation score was defined as the sum of the synovitis, tenosynovitis and BME score in that specific joint (for more information on possible scores per imaged joint see supplementary data, section Methods, available at Rheumatology online). The MTP joints were not included in the analyses on joint level because of the above-mentioned limitations of the scan protocol of the feet. In order to study the prevalence of MRI-detected subclinical inflammation, continuous MRI scores were dichotomized on joint level; subclinical inflammation was considered present if the mean scores of two readers was 51 and considered absent in case of mean scores <1 for either synovitis, tenosynovitis or BME separately. Any type of inflammation was considered present if the mean score of one of the different types of inflammation was 51.
Joint pain
Three different measures for pain were studied. The overall severity of joint pain at patient level was measured using a visual analogue scale (VAS, range 010) at the time of inclusion. The primary measure for pain at joint level was obtained from the 68-TJC that was assessed by a trained research nurse at baseline; information on the unilateral MCP and wrist joints that were imaged was extracted. Thus, only information of joint tenderness of the imaged MCP (25) joints and imaged wrist was extracted from the 68-TJC. Hence, joints typical for osteoarthritis, such as the DIP joints and CMC joint were not included in analyses at joint level. In addition, as patient-reported joint pain might differ from tenderness obtained at joint examination, a patient-reported joint count (68 joints) was added to the clinically suspect arthralgia protocol in April 2015. Also from the patient-reported joint counts, information on the imaged wrist and MCP joints was retrieved. Patient-reported pain was available for 156 (48%) patients; missingness was considered to be completely at random.
Statistical analyses
At patient level linear regression was used to study associations between MRI-detected inflammation (independent variable) and the VAS pain (dependent variable). All types of MRI-detected inflammation were entered separately in univariable analyses. Subsequently these data were entered together in a multivariable analysis as several types of MRI-detected inflammation frequently occur together (supplementary Fig. S1 , available at Rheumatology online). At joint level general estimated equations (GEEs) were used to study associations between local MRI-detected inflammation and joint tenderness, as this method allows adjustment for the fact that each patient contributed multiple joints. All GEEs were corrected for age and gender. Also, in GEEs different types of MRI-detected inflammation were entered separately and then together in a multivariable model. As the 68-TJC was missing in 1 patient, 324 patients were included in these analyses, all contributing five joints (MCP (25) and wrist), resulting in 1620 studied joints. Analyses were repeated stratified for ACPA [1315] . As a sensitivity analysis, patients that developed inflammatory arthritis were studied separately as the joint symptoms in these patients were truly a first sign of inflammatory arthritis. Until 1 December 2017, 61 patients had developed inflammatory arthritis after a median follow-up of 3 (interquartile range 15) months. The median follow-up of patients who did not develop arthritis during follow-up was 2 years (range 0.22). Therefore, no comparisons could be made between patients who did and who did not develop arthritis as we expect that some patients may still develop arthritis during further follow-up.
Results
Baseline characteristics
Baseline characteristics of all 325 clinically suspect arthralgia patients who fulfilled the EULAR definition for arthralgia suspicious for progression to RA are depicted in Table 1 . The majority of patients were female, the mean age was 44 years, the median 68-TJC at joint examination was 6 and the mean VAS pain 5.2.
Associations between subclinical inflammation and joint pain at patient level At patient level, synovitis (b = 0.10, P = 0.048) and tenosynovitis (b = 0.11, P = 0.026) were significantly associated with the VAS pain in univariable analysis. A b of 0.10 for synovitis means that a 1-point increase in the MRIdetected synovitis score was associated with a 0.10-point higher VAS pain ( Table 2 ). None of these variables was associated with pain independent of the others in multivariable analysis (Table 2) .
Associations between subclinical inflammation and tenderness or pain at joint level At joint level (n = 1620 joints), GEEs adjusted for age and gender were used to study associations between MRIdetected inflammation and joint tenderness. This was done to study if the joints that were tender also showed more subclinical inflammation. The total inflammation score was associated with tenderness at joint examination (odds ratio (OR) 1.13, P = 0.001, Table 3 ) in univariable analysis. Further separation by type of MRI-detected inflammation revealed associations with synovitis (OR 1.64, P < 0.001) and tenosynovitis (OR 1.17, P = 0.011), but not In May 2015 a patient-reported joint count (assessing 68 joints) was added to the clinically suspect arthralgia protocol and was collected in 156 consecutive patients.
b The imaged joints were four MCP joints and one wrist per patient, thus five joints in total. Missings were as follows: VAS pain (20) , ACPA (2), RF (3), 68-TJC (1) and patient-reported joint pain (169). 68-TJC: 68 tender joint count; BME: bone marrow oedema; VAS: visual analogue scale; IQR: interquartile range.
with BME (OR 1.08, P = 0.58). As the different types of MRI-detected inflammation often occur together (supplementary Fig. S1 , available at Rheumatology online), these were entered together in a multivariable analysis, showing that synovitis remained independently associated with joint tenderness (OR 1.74, P < 0.001).
Next, the association between patient-reported pain at joint level and MRI-detected inflammation was assessed and similar findings were obtained; only synovitis remained independently associated with patient-reported joint pain (OR 2.03, P = 0.001, Table 3 ).
Prevalence of subclinical inflammation in tender and in non-tender joints
The data obtained so far revealed associations between subclinical inflammation and pain in arthralgia patients at risk for RA. Next, in order to determine how often subclinical inflammation was present in tender and in non-tender joints, the prevalence of subclinical inflammation was assessed after dichotomizing the continuous MRI scores. Any type of subclinical inflammation was present in 434/ 1620 (27%) of all studied joints. The prevalence was higher in tender joints 141/447 (32%) joints than in nontender joints 293/1173 (25%). All types of MRI-detected inflammation separately were more frequent in tender joints than in non-tender joints (22 vs 14% for synovitis, 17 vs 14% for tenosynovitis and 8 vs 7% for BME, Fig. 1A ).
Analyses stratified by ACPA status ACPA-positive clinically suspect arthralgia patients had a median 68-TJC of 5 and a mean VAS pain of 5.6; in ACPAnegative patients these were 6 and 5.2, respectively. Analyses on joint level were repeated, stratified by ACPA status. In univariable GEEs analysis, the total inflammation score at joint level was associated with tenderness (as assessed at physical examination of joints) both in ACPA-positive (OR 1.28, P = 0.010) and in ACPA-negative clinically suspect arthralgia (OR 1.12, P = 0.006) ( Table 4) . Within ACPA-positive patients both tenosynovitis (OR 1.36, P = 0.041) and BME (OR 2.47, P = 0.001) were associated with tenderness in univariable analysis. In multivariable analysis only BME remained independently associated with tenderness (OR 2.39, P = 0.005). Within ACPA-negative clinically suspect arthralgia both synovitis (OR 1.72, P < 0.001) and tenosynovitis (OR 1.18, P = 0.026) were associated with tenderness in univariable analysis, and synovitis showed an independent association in multivariable analysis (OR 1.96, P < 0.001) ( Table 4 ).
Sub-analysis in patients who developed inflammatory arthritis during follow-up
Finally, analyses were repeated in 61 patients who developed inflammatory arthritis during follow-up. At patient level, synovitis tended to be associated with the VAS pain in univariable analysis (b = 0.18, P = 0.053) (supplementary Table S2 , available at Rheumatology online). A total of 305 joints were studied of which 73 (24%) were tender. The total inflammation score was associated with joint tenderness (OR 1.27, P = 0.001, Table 5 ). The different types of MRI-detected inflammation taken separately were also associated with tenderness (synovitis: OR 1.97, P = 0.003; tenosynovitis: OR 1.35, P = 0.019; and BME: OR 2.21, P = 0.004, Table 5 ), although statistical significance was lost in multivariable analysis (Table 5) . Fortytwo percent of the small joints imaged had subclinical inflammation; it was present in 51% of the tender joints and in 39% of the non-tender joints. All types of MRI-detected inflammation were more prevalent in tender joints than in non-tender joints (Fig. 1B) .
Discussion
In this large cross-sectional MRI study we aimed to improve our understanding of the aetiology of symptoms in patients with arthralgia suspicious for progression to RA. We observed that subclinical MRI-detected inflammation, synovitis in particular, is associated with pain, at both patient and at joint level. In addition, different associations were observed in ACPA-positive and ACPA-negative patients. Whereas BME (osteitis) was independently associated with joint tenderness in ACPA-positive clinically suspect arthralgia, synovitis was independently associated with tenderness in ACPA-negative clinically suspect arthralgia, suggesting different pathways for pain in both subtypes. This study also demonstrated that subclinical inflammation was absent in a large proportion of tender joints; this concerned 49% of the joints imaged at first presentation with clinically suspect arthralgia in patients that did progress to inflammatory arthritis over time. This indicates that the presence of subclinical inflammation cannot fully explain the aetiology of joint symptoms in these patients. However, this finding is not different from that obtained in the phase of early arthritis, as a previous study on patients presenting with arthritis of recent onset showed that 5159% of tender hand or foot joints did not show MRIdetected inflammation [23] . Explanations for pain other than subclinical inflammation need to be investigated and considered, such as referred pain from spinal pathology for example.
To our best knowledge, this is the first study to reveal that associations between subclinical inflammation and joint pain are different for ACPA-positive and ACPA-negative patients. Furthermore, because of the large number of patients and available MRIs (n = 325) it was possible to correct for the combined presence of synovitis, tenosynovitis and BME in multivariable analyses. Previously, two small MRI studies have been performed [10, 11] and observed a univariable association between joint tenderness and subclinical synovitis in ACPA-negative clinically suspect arthralgia, which is in line with our results. A large ultrasound study also observed an association between subclinical synovitis and tenderness in seropositive arthralgia [12] , but a downside of ultrasound is that it cannot visualize BME. Also, tenosynovitis was not assessed in this study. Thus, the finding that joint pain is partly explained by subclinical synovitis is in line with previous findings, although more thoroughly explored in the present study. In contrast, the finding that in ACPA-positive arthralgia BME (osteitis) is associated with joint tenderness independent of synovitis and tenosynovitis is novel.
While the relation between BME and erosive progression has been widely established [2426] , the association between BME and pain in ACPA-positive arthralgia has not been reported before. As the bone marrow is not innervated, it remains to be determined how to explain this finding. A histologic study in 11 RA patients revealed an increased number of osteoclasts in bone samples in which MRI-detected BME was present, showing that BME in RA truly is inflammation (therefore called osteitis) [27] .
FIG. 1 Prevalence of MRI-detected inflammation in (A) all patients and in (B) patients who developed inflammatory arthritis
The bars depict the prevalence of subclinical inflammation in tender joints (striped) and in non-tender joints (diamonds) at physical examination. In the upper panel all studied patients (n = 325) are included and in the lower panel only patients who developed inflammatory arthritis during follow-up were included (n = 61). BME: bone marrow oedema.
Although histologic studies in clinically suspect arthralgia have not been performed, BME in clinically suspect arthralgia might also be considered as osteitis. Recent mice data have suggested that ACPAs can bind osteoclasts and stimulate CXCL-1 and IL-8 release and that this in turn can produce pain by activating sensory neurons [28] . Whether such ACPA-dependent pathways for pain play a role in humans during the development of RA requires further investigation. Surprisingly, within ACPA-negative clinically suspect arthralgia, BME was inversely associated with joint tenderness in multivariable analysis; possibly collinearity contributed to this effect. Furthermore, in line with previous studies on the aetiopathology of RA, our results on subclinical inflammation and symptoms in patients with clinically suspect arthralgia emphasize the notion that ACPA-positive and ACPAnegative RA are different subsets of disease with differences in underlying biologic mechanisms [14, 15] .
Thus far, differences between ACPA-positive and ACPA-negative RA have been shown for genetic and environmental risk factors and differences in the synovial infiltrate [13, 14, 29] . In the symptomatic pre-arthritis phase, some clinical differences have been shown recently [15] . In addition, this study shows that joint tenderness is associated with different inflammatory features in ACPA-positive and ACPA-negative arthralgia. Further studies are needed to evaluate whether there are also histological differences in the joint in this symptomatic pre-arthritis phase.
Although this study was cross-sectional in nature, a strength is the fact that we were able to perform a sensitivity analysis in patients who developed arthritis during follow-up, as (in retrospect) these patients truly were in a pre-arthritis phase. Results in this subgroup were similar to those in the whole population of clinically suspect arthralgia patients studied. A single difference is that univariable analysis in this subgroup showed a significant association for BME, which was not the case in the whole group. Presumably this is explained by the higher prevalence of ACPA-positivity in the subgroup (30 vs 11%). Importantly, a portion of the patients that did not progress to inflammatory arthritis had a limited follow-up duration. Therefore, the nature of the data did not allow comparison of the patients that progressed to inflammatory arthritis with those that did not progress, as misclassification might be present in the latter group. Results of univariable and multivariable GEEs with joint tenderness as reported by a trained research nurse was taken as the outcome. All analyses are corrected for age and gender. BME: bone marrow oedema; GEE: general estimated equations; OR: odds ratio.
Likewise, the current percentage of inflammatory arthritis development (19%) may be underestimated. There are different ways to define the presence of subclinical inflammation. In this study, subclinical inflammation was considered present if the mean score of two readers on either synovitis, tenosynovitis or BME on a specific joint location was 51. Thus the definition used ignored the fact that some low-graded subclinical inflammation is also present in symptom-free controls, especially at higher age [30] . Because we observed that subclinical inflammation was present in non-tender joints, we wondered whether this inflammation was similar to that observed in symptom-free controls. Repeating the analyses using a definition of subclinical inflammation that incorporated findings of the normal population as described previously [31] did not change the results (supplementary Fig. S2 , available at Rheumatology online).
There are limitations to the present study. While we can reveal associations between pain and subclinical inflammation, we cannot prove causality based on our current data. In addition, although the total study population was relatively large, patient numbers in subgroups were small, possibly leading to lack of power in multivariable analyses. For example, in the subgroup of patients who developed inflammatory arthritis the effect sizes of the associations between subclinical inflammation and pain were larger than those in the total group of patients, but CIs were wider and P-values higher in multivariable analysis. Therefore, larger studies are needed in patients who developed inflammatory arthritis during follow-up. Furthermore, longitudinal MRI data were not available. This would be of interest for future studies in order to study whether changes in subclinical inflammation cooccur with changes in pain and vice versa. Finally, we did not include the MTP joints in our analyses on joint level, mostly because of limitations in our MRI scanning protocol for the feet in some of the patients [32] . Exploring whether the association between foot pain or local tenderness and MRI-detected subclinical inflammation is different from the observed associations in the hand joints is also a subject for future research.
In sum, this cross-sectional MRI study in patients with arthralgia suspicious for progression to RA revealed associations between pain and subclinical inflammation. This association was strongest for synovitis in the total group and ACPA-negative patients, while in the subset of ACPApositive arthralgia patients, BME (osteitis) was independently associated with joint pain. However, as subclinical inflammation was absent in part of the tender joints, the aetiology of joint symptoms in the symptomatic phase preceding RA development cannot fully be explained by the presence of subclinical inflammation.
